BioMarin Pharmaceutical (BMRN) Price Target Raised to $145 at RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study
June 17, 2015 4:01 PM EDT- 50% Increase in mean annualized growth velocity in 15 µg/kg/daily dose group
- BMN 111 was well tolerated across all three dose cohorts
- Phase 2 findings support program advancement of 15µg/kg/daily dose into pivotal registration discussions with health authorities
- Investor conference call to be held today, June 17, 2015 at 1:30pm PT/(4:30pm ET)
SAN RAFAEL, Calif., June 17, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111... More
